Recent evidence indicates that cyclophosphamide exposure increases the risk of hematologic malignancies in patients with rheumatoid arthritis. In a large administrative database cohort of patients ...

A study by Mellqvist et al. has assessed the efficacy and safety of combined bolus-dose cyclophosphamide and pulse-dose dexamethasone (Cy-Dex) as initial treatment for patients with myeloma.

Cyclophosphamide is widely used to treat severe manifestations of numerous autoimmune rheumatic diseases including systemic sclerosis. Based on recent data, immunological and inflammatory ...